Hyderabad: Dr. Reddy’s Laboratories Ltd has announced an investment of Rs 565.4 crore in its step-down wholly owned ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Dr Reddy's Laboratories share price gained almost 3% in the morning trades on Thursday post Q1 results that were declared ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

The focus has now shifted to Semaglutide, the GLP-1 agonist being pursued as a generic version of Ozempic/Wegovy.

Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it ...

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is one of the Best Indian Stocks to Buy for Next 5 Years. Dr. Reddy’s ...

The company is going to announce results for the quarter ended June 30th, 2025 on July 23, 2025 after the board meeting.

Leading pharmaceutical major Dr Reddys Laboratories is set to announce its Q1FY26 financial results on. Markets top analysts ...

Leading pharmaceutical companies, Sun Pharma, Dr Reddy's Laboratories and Lupin are recalling products from the US market due ...

Best case scenario, Semaglutide can garner $500 million sales in FY27, HSBC said. It added that Dr Reddy's will be among the ...

Stocks including Kotak Mahindra Bank, RITES, IndusInd Bank, IDFC First Bank, Dr Reddy's Labs, CDSL, Bank of Baroda, SAIL and ...